NCT00357682View on ClinicalTrials.gov

A Phase III, Randomized, Study of Aspirin and Esomeprazole Chemoprevention in Barrett's Metaplasia

PHASE3CompletedINTERVENTIONAL
Enrollment

2,557

Participants

Timeline

Start Date

March 10, 2005

Primary Completion Date

May 31, 2017

Study Completion Date

May 31, 2017

Conditions
Esophageal CancerPrecancerous Condition
Interventions
DRUG

Esomeprazole

20mg per day

DRUG

Esomeprazole

80mg per day

DRUG

Aspirin

300mg per day

Sponsors

Collaborators (1)

AstraZeneca
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

lead

University of Oxford

OTHER